Papillary thyroid microcarcinoma with lymph node extension
Place of iratherapy
Versandkostenfrei!
Versandfertig in 6-10 Tagen
40,99 €
inkl. MwSt.
PAYBACK Punkte
20 °P sammeln!
The management of differentiated thyroid cancers is a hotly debated topic, especially when it comes to defining the best treatment modalities using radioactive iodine as a complement to surgery. Papillary thyroid micro-carcinomas (PCM) with lymph node extension are no exception to this rule. While there is a consensus for low-risk PCMs, therapeutic attitudes diverge as to complementary iratherapy for intermediate- to high-risk PCMs.We conducted a study to evaluate the post-surgical complementary iratherapy protocol proposed for patients followed for PCM with lymph node extension in the Nuclear...
The management of differentiated thyroid cancers is a hotly debated topic, especially when it comes to defining the best treatment modalities using radioactive iodine as a complement to surgery. Papillary thyroid micro-carcinomas (PCM) with lymph node extension are no exception to this rule. While there is a consensus for low-risk PCMs, therapeutic attitudes diverge as to complementary iratherapy for intermediate- to high-risk PCMs.We conducted a study to evaluate the post-surgical complementary iratherapy protocol proposed for patients followed for PCM with lymph node extension in the Nuclear Medicine Department of the Salah Azaiez Institute. These patients underwent either high-dose or low-dose complementary iratherapy, with a 6-month post-cure and long-term evaluation. We concluded that the efficacy of low-dose treatment was non-inferior to that of high-dose treatment for patients followed for PCM with lymph node extension.
Andere Kunden interessierten sich für
